Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Devimistat + Modified FOLFIRINOX in Metastatic Pancreatic Cancer
NCT05926206Phase 2Withdrawn
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 2023
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of devimistat in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by University of Michigan Rogel Cancer Center. Primary endpoints: Dose-Limiting Toxicity at 15 days and Progression-Free Survival at 42 months. Planned start Jul 2023; status: withdrawn.
02
Drugs
devimistat
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05926206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05926206.